Mike joined Sofinnova as an Analyst and was promoted to Associate in 2024. He focuses on biopharmaceutical companies and investments.
Prior to joining Sofinnova in 2022, Mike completed his PhD in Biology at Stanford University working in the laboratory of Lacramiora Bintu, where he merged high-throughput screening assays and synthetic biology techniques to develop new CRISPR-based epigenome editing tools. While at Stanford, Mike was a venture fellow at Sofinnova and has consulted for numerous roles across the biotech industry, including business development with Maze Therapeutics, assay development with Octant, and product development with Wearlinq, a heart monitoring startup. Mike was also a managing partner of the Mythos Biotechnology Fund, a student-led public biotech investment club.
Mike received his PhD in Biology from Stanford University. Mike also holds a BS in Biochemistry and Molecular Biology from the University of California, Davis.